The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older
Open accessAbstract
BACKGROUND: Although nephrectomy cures most localized renal cancers, this oncologic benefit may be outweighed by the renal functional costs of such an approach. In this study, the authors examined overall survival in 537 patients who had localized renal tumors ≤7 cm detected at age ≥75 years to investigate whether surgical intervention improved survival compared with active surveillance. METHODS: Clinical T1 renal tumors were managed with surveillance (20%), nephron‐sparing interventions (53%), or nephrectomy (27%). Cox regression models were constructed based on age, comorbidity, management type, renal function, and other variables. RESULTS: The median follow‐up was 3.9 years, and death from any cause occurred in 148 patients (28%). The most common cause of death was cardiovascular (29%), and cancer progression was responsible in only 4% of deaths. Kaplan‐Meier analysis revealed decreased overall survival for patients who underwent surveillance and nephrectomy relative to nephron‐sparing intervention ( P = .01); however, surveilled patients were older and had greater comorbidity. In multivariate analysis, significant predictors of overall survival included age ( P = .0004) and comorbidity ( P < .0001) but not management type ( P = .3). Preoperative renal function ( P = .006) and comorbidity ( P = .005) were predictors of cardiovascular mortality, and nephrectomy was associated with greatest loss of renal function. CONCLUSIONS: In patients aged ≥75 years, surgical management of clinically localized renal cortical tumors was not associated with increased survival. Patients died mostly of cardiovascular causes, similar to the general elderly population. Nephrectomy accelerated renal dysfunction, which was associated with cardiovascular mortality. Current paradigms suggest that there is over treatment of localized renal tumors, and further study will be required to evaluate the advisability of various options in patients with limited life expectancy. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
editor-in-chief, A. J. W. (2012) · Elsevier eBooks · Cited by 2,682
Rising Incidence of Renal Cell Cancer in the United States
Chow, W.-H. (1999) · JAMA · doi:10.1001/jama.281.17.1628 · Cited by 1,586
Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect
Hollingsworth, J. M., Miller, D. C., Daignault, S., & Hollenbeck, B. K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj362 · Cited by 1,173
Huang, W. C., Elkin, E. B., Levey, A. S., Jang, T. L., & Russo, P. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.09.017 · Cited by 838
Lau, W. K. O., Blute, M. L., Weaver, A. L., Torres, V. E., & Zincke, H. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.12.1236 · Cited by 755
Thompson, R. H., Boorjian, S. A., Lohse, C. M., Leibovich, B. C., Kwon, E. D., Cheville, J. C., & Blute, M. L. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.09.077 · Cited by 713
SURGICAL MANAGEMENT OF RENAL TUMORS 4 CM. OR LESS IN A CONTEMPORARY COHORT
LEE, C. T., KATZ, J., SHI, W., THALER, H. T., REUTER, V. E., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67793-2 · Cited by 638
Natural history of chronic renal insufficiency after partial and radical nephrectomy
McKiernan, J., Simmons, R., Katz, J., & Russo, P. (2002) · Urology · doi:10.1016/s0090-4295(02)01501-7 · Cited by 533
Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Gönen, M., Ruan, S., Pierre, C., Nagel, A., Pryma, D. A., Humm, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70044-x · Cited by 387
CURB, J. D., FORD, C. E., PRESSEL, S., PALMIER, M., BABCOCK, C., & HAWKINS, M. (1985) · American Journal of Epidemiology · doi:10.1093/aje/121.5.754 · Cited by 204
Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer
Raj, G. V., Thompson, R. H., Leibovich, B. C., Blute, M. L., Russo, P., & Kattan, M. W. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.01.101 · Cited by 126
Pettus, J. A., Jang, T. L., Thompson, R. H., Yossepowitch, O., Kagiwada, M., & Russo, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.10.1101 · Cited by 82
Cryoablation for renal tumors: current status
Berger, A., Kamoi, K., Gill, I. S., & Aron, M. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e328323f618 · Cited by 55
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 571
Metadata
- Authors
- Lane, B. R., Abouassaly, R., Gao, T., Weight, C. J., Hernandez, A. V., Larson, B. T., Kaouk, J. H., Gill, I. S., & Campbell, S. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-05-10
- Volume
- 116
- Issue
- 13
- Pages
- 3119-3126
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1974788327
- Cited by
- 260
- References
- 16
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.